Evaluation of different preparation procedures of pathogen reduction technology(Mirasol®)-Treated platelets collected by plateletpheresis

Transfusion Medicine and Hemotherapy

Volumn 36, Issue 5, 2009, Pages 309-315

  Janetzko, Karin ^a   Hinz, Katharina ^a   Marschner, Susanne ^b   Goodrich, Ray ^b   Klüter, Harald ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CaridianBCT Biotechnologies   (United States)

Author keywords

Mirasol ; Pathogen inactivation; Pathogen reduction; Platelet concentrates; Riboflavin

Indexed keywords

GLUCOSE; LACTATE DEHYDROGENASE; LACTIC ACID; PADGEM PROTEIN; RIBOFLAVIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ARTICLE; DEVICE; GLUCOSE METABOLISM; HUMAN; MEDICAL TECHNOLOGY; PH; PLASMA; THROMBOCYTE METABOLISM; THROMBOCYTE PRESERVATION; THROMBOCYTOPHERESIS; ULTRAVIOLET RADIATION;

EID: 70449346708     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000230038     Document Type: Article

References (26)

1. Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Marin CB, Ravanat JL, Cadet J, Goodrich RP: Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004;80:15-21.
2. Tsugita A, Okada Y, Uehara K: Photosensitized inactivation of nucleic acids in the presence of riboflavin. Biochem Biophys Acta 1965;103:360-363.
3. Cadet J, Decarroz C, Wang SY, Midden WR: Mechanisms and products of photosensitized degradation of nucleic acids and related models compounds. Israel J Chem 1983;23:420-429.
4. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard L, Goodrich RP: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-885.
5. Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendes J, Reddy H, Goodrich RP: Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006;90:85-91.
6. Fast LD, DiLeone G, Li J, Goodrich RP: Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006;46:642-648.
7. Maurer-Spurej E, Chiperfield K: Past and future approaches to assess the quality of platelets for transfusion. Transfus Med Rev 2007;21:295-306.
8. Klinger MHF: The storage lesion of platelets: ultrastructural and functional aspects. Ann Hematol 1996;73:103-112.
9. Seghatchian J, Krailadsiri P: The platelet storage lesion. Transfus Med Rev 1997;11:130-144.
10. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP: Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-1341.
11. Li J, de Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP: Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen reduction technology-treated apheresis platelet products. Vox Sang 2004;87:82-90.
12. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich RP, Escolar G: Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005;45:911-919.
13. Curvers J, van Pampus EC, Feijge MA, Rombout- Sestrienkova E, Giesen PL, Heemskerk JW: Decreased responsiveness and development of activation markers of PLTs stored in plasma. Transfusion 2004;44:49-58.
14. Cauwenberghes S, Van Pampus E, Curvers J, Akkerman JWN, Heemskerk JWM: Hemostatic and signalling functions of transfused platelets. Transfus Med Rev 2007;21:287-294.
15. Rinder HM, Murphy M, Mitchell JG, Stocks J, Ault KA, Hillman RS: Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion 1991;31:409-414.
16. Holme S, Sweeney JD, Sawyer S, Elfath MD: The expression of p-selectin during collection, processing and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997;37:12-17.
17. Michelson AD, Barnard MR, Hechtman HB, Mac- Gregor H, Connolly RJ, Loscalzo J, Valeri CR: In vivo tracking of platelets: circulating degranulated platelets rapidly lose surfact p-selctin but continue to circulate and function. Proc Natl Acad Sci U S A 1996;93:11877-11882.
18. Berger G, Hartwell DW, Wagner DD: P-selectin and platelet clearance. Blood 1998;92:4446-4452.
19. Leytin V, Allen DJ, Gwozdz A, Garvey B, Freedman J: Role of platelet surface glycoprotein Ib alpha and p-selectin in the clearance of transfused platelet concentrates. Transfusion 2004;44:1487-1495.
20. Larson E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, Wagner DD, Furie B: PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989;59:305-312.
21. Mehta P, Patel KD, Laue TM, Erikson HP, McEver RP: Soluble monomeric p-selectin containing only the lectin and epidermal growth factor domains bind to p-selectin glycoprotein ligand-1 on leukocytes. Blood 1997;90:2381-2389.
22. Stohlawetz P, Hergovich N, Stiegler G, Eichler HG, Höcker P, Kapiotis S, Jilma B: Differential induction of p-selectin expression on platelets by two cell separators during plateletpheresis and the effect of gender on the release of soluble p-selectin. Transfusion 1998;38:24-30.
23. Klinger MHF, Josch M, Klüter H: Platelets stored in a glucose-free additive solution or in autologous plasma - an ultrastructural and morphometric evaluation. Vox Sang 1996;71:13-20.
24. Council of Europe: Guide to the preparation, use and quality assurance of blood components, ed 14. Strasbourg, Council of Europe Publishing, 2008.
25. Bundesärztekammer: Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Gesamtnovelle 2005 mit Änderungen und Ergänzungen 2007. Köln, Deutscher Ärzte-Verlag, 2007.
26. Goodrich RP, Folléa G, Robert T: Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008;48s: 20A.